1
|
Somboro AM, Cissoko Y, Camara I, Kodio O, Tolofoudie M, Dembele E, Togo ACG, Ba DM, Sarro YDS, Baya B, Samake S, Diallo IB, Kumar A, Traore M, Kone B, Kone A, Diarra B, Dabitao DK, Wague M, Dabo G, Doumbia S, Holl JL, Murphy RL, Diallo S, Maiga AI, Maiga M, Dao S. High SARS-CoV-2 Seroprevalence among Healthcare Workers in Bamako, Mali. Viruses 2022; 14:v14010102. [PMID: 35062306 PMCID: PMC8780908 DOI: 10.3390/v14010102] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 12/25/2021] [Accepted: 12/27/2021] [Indexed: 02/05/2023] Open
Abstract
In Mali, a country in West Africa, cumulative confirmed COVID-19 cases and deaths among healthcare workers (HCWs) remain enigmatically low, despite a series of waves, circulation of SARS-CoV-2 variants, the country’s weak healthcare system, and a general lack of adherence to public health mitigation measures. The goal of the study was to determine whether exposure is important by assessing the seroprevalence of anti-SARS-CoV-2 IgG antibodies in HCWs. The study was conducted between November 2020 and June 2021. HCWs in the major hospitals where COVID-19 cases were being cared for in the capital city, Bamako, Mali, were recruited. During the study period, vaccinations were not yet available. The ELISA of the IgG against the spike protein was optimized and quantitatively measured. A total of 240 HCWs were enrolled in the study, of which seropositivity was observed in 147 cases (61.8%). A continuous increase in the seropositivity was observed, over time, during the study period, from 50% at the beginning to 70% at the end of the study. HCWs who provided direct care to COVID-19 patients and were potentially highly exposed did not have the highest seropositivity rate. Vulnerable HCWs with comorbidities such as obesity, diabetes, and asthma had even higher seropositivity rates at 77.8%, 75.0%, and 66.7%, respectively. Overall, HCWs had high SARS-CoV-2 seroprevalence, likely reflecting a “herd” immunity level, which could be protective at some degrees. These data suggest that the low number of cases and deaths among HCWs in Mali is not due to a lack of occupational exposure to the virus but rather related to other factors that need to be investigated.
Collapse
Affiliation(s)
- Anou M. Somboro
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Private Bag X5, Durban 4001, South Africa
- Correspondence: (A.M.S.); (M.M.); Tel.: +1-847-467-2560 (M.M.)
| | - Yacouba Cissoko
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
- Department of Infectious Diseases and Tropical Medicine, Point “G” University Teaching Hospital, Bamako PB 1805, Mali
| | - Issiaka Camara
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Ousmane Kodio
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Mohamed Tolofoudie
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Etienne Dembele
- Institute for Global Health, Northwestern University, Chicago, IL 60611, USA; (E.D.); (A.K.); (M.T.); (R.L.M.)
| | - Antieme C. G. Togo
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Djibril M. Ba
- Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033, USA;
| | - Yeya dit Sadio Sarro
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Bocar Baya
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Seydou Samake
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Ibrahim B. Diallo
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Alisha Kumar
- Institute for Global Health, Northwestern University, Chicago, IL 60611, USA; (E.D.); (A.K.); (M.T.); (R.L.M.)
| | - Mohamed Traore
- Institute for Global Health, Northwestern University, Chicago, IL 60611, USA; (E.D.); (A.K.); (M.T.); (R.L.M.)
| | - Bourahima Kone
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Amadou Kone
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Bassirou Diarra
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Djeneba K. Dabitao
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Mamadou Wague
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Garan Dabo
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Seydou Doumbia
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Jane L. Holl
- Department of Neurology and Center for Healthcare Delivery Science and Innovation, University of Chicago, Chicago, IL 60611, USA;
| | - Robert L. Murphy
- Institute for Global Health, Northwestern University, Chicago, IL 60611, USA; (E.D.); (A.K.); (M.T.); (R.L.M.)
| | - Souleymane Diallo
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Almoustapha I. Maiga
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
| | - Mamoudou Maiga
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
- Institute for Global Health, Northwestern University, Chicago, IL 60611, USA; (E.D.); (A.K.); (M.T.); (R.L.M.)
- Correspondence: (A.M.S.); (M.M.); Tel.: +1-847-467-2560 (M.M.)
| | - Sounkalo Dao
- University Clinical Research Center (UCRC) Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako PB 1805, Mali; (Y.C.); (I.C.); (O.K.); (M.T.); (A.C.G.T.); (Y.d.S.S.); (B.B.); (S.S.); (I.B.D.); (B.K.); (A.K.); (B.D.); (D.K.D.); (M.W.); (G.D.); (S.D.); (S.D.); (A.I.M.); (S.D.)
- Department of Infectious Diseases and Tropical Medicine, Point “G” University Teaching Hospital, Bamako PB 1805, Mali
| |
Collapse
|
2
|
Tolofoudie M, Somboro A, Diarra B, Sarro YS, Drame HB, Togo ACG, Sanogo M, Dembele A, Togun T, Nkereuwem E, Baya B, Konate B, Egere U, Traore M, Maiga M, Saliba-Shaw K, Kampmann B, Diallo S, Doumbia S, Sylla M. Isoniazid preventive therapy in child household contacts of adults with active TB in Bamako, Mali. Public Health Action 2021; 11:191-195. [PMID: 34956847 PMCID: PMC8680184 DOI: 10.5588/pha.21.0061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 08/16/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Isoniazid preventive therapy (IPT) is known to reduce the risk of developing active TB in about 59% in children aged ⩽15 years. We assessed adherence, completion and adverse events among children who were household contacts of a newly diagnosed adult with smear-positive TB in Bamako, Mali. METHODS Children aged <15 years living in the same house with an adult smear-positive index case were enrolled in the study in the Bamako Region after consent was obtained from the parent or legal guardian. Adherence was assessed based on the number of tablets consumed during 6 months. RESULTS A total of 260 children aged <15 years were identified as household contacts of 207 adult patients with smear-positive TB during the study period. Among all child contacts, 130/260 (50.0%) were aged 0-4 years and were eligible for IPT; 128/130 (98.5%) were started on IPT and 83/128 (64.8%) completed with good adherence at the end of the 6 months, and without any significant adverse events. CONCLUSION We successfully implemented IPT with good acceptance, but low completion rate. The Mali National TB Program and partners should expand this strategy to reach more children in Bamako and the whole country and create greater awareness in the population.
Collapse
Affiliation(s)
- M Tolofoudie
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Somboro
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Diarra
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - H B Drame
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Dembele
- Department of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali
| | - T Togun
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - E Nkereuwem
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - B Baya
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Konate
- National Tuberculosis Control Program, Ministry of Health and Public Hygiene, Bamako, Mali
| | - U Egere
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - M Traore
- Health Referral Center Five, Ministry of Health and Social Development, Bamako, Mali
| | - M Maiga
- Center for Innovation in Global Health Technology, Northwestern University, Chicago, IL, USA
| | - K Saliba-Shaw
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA
| | - B Kampmann
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - S Diallo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sylla
- Department of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali
| |
Collapse
|
3
|
Diarra B, Decroo T, Somboro A, Coulibaly G, Tolofoudie M, Kone M, Degoga B, Diallo F, Togo ACG, Sanogo M, Sarro YS, Cisse AB, Kodio O, Baya B, Kone A, Maiga M, Dao S, Maiga II, Murphy RL, Siddiqui S, Toloba Y, Konate B, Diakite M, Doumbia S, Van Deun A, Rigouts L, Diallo S, de Jong BC. Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. Int J Tuberc Lung Dis 2021; 24:763-769. [PMID: 32912379 DOI: 10.5588/ijtld.19.0698] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.
Collapse
Affiliation(s)
- B Diarra
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali, Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp
| | - T Decroo
- Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Antwerp, Research Foundation Flanders, Brussels, Belgium
| | - A Somboro
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - G Coulibaly
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Tolofoudie
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Kone
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Degoga
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - F Diallo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A B Cisse
- Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali
| | - O Kodio
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Baya
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Kone
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Maiga
- Global Health, Northwestern University, Chicago, IL, USA
| | - S Dao
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - I I Maiga
- Laboratoire d´analyses Médicales et Hygiène Hospitalière du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - R L Murphy
- Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali
| | - S Siddiqui
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Y Toloba
- Service de Pneumo-phtisiologie du Centre Hospitalier Universitaire du Point-G, Bamako
| | - B Konate
- Programme National de Lutte contre la Tuberculose (PNLT), Ministère de la santé et des Affaires Sociales, Bamako, Mali
| | - M Diakite
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | | | - L Rigouts
- Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - S Diallo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B C de Jong
- Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp
| |
Collapse
|
4
|
Coulibaly N, Kone B, Sanogo M, G Togo AC, Diarra B, Sarro YS, Cisse AB, Kodio O, Coulibaly G, Kone M, Baya B, Maiga M, Dabitao D, Belson M, Dao S, Diallo S, Diakite M, Babana AH, Doumbia S. Performance of Mali's biosafety level 3 laboratory in the external quality assessment in preparedness of laboratory accreditation and support to clinical trials. Int J Mycobacteriol 2021; 9:29-33. [PMID: 32474485 PMCID: PMC8075184 DOI: 10.4103/ijmy.ijmy_5_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Background: The external quality assessment (EQA) or external quality control is an evaluation conducted by a certified external organization to inquire about the quality of the results provided by a laboratory. The primary role of EQA is to verify the accuracy of laboratory results. This is essential in research because research data should be published in international peer-reviewed journals, and laboratory results must be repeatable. In 2007, the University Clinical Research Center (UCRC’s) biosafety level 3 (BSL-3) laboratory joined the EQA program with the College of American Pathologists in acid-fast staining and culture and identification of mycobacteria as per laboratory accreditation preparedness. Thus, after 11 years of participation, the goal of our study was to evaluate the performance of our laboratory during the different interlaboratory surveys. Methods: We conducted a descriptive retrospective study to evaluate the results of UCRC mycobacteriology laboratory from surveys conducted during 2007 and 2017. Results: Of the 22 evaluations, the laboratory had satisfactory (100% of concordance results) in 18 (81.8%) and good (80% of concordance results) in 4 (18.2%). Overall, the laboratory was above the commended/accepted limits of 75%. Conclusion: So far, UCRC’s BSL-3 performed well during the first 11 years of survey participation, and efforts should be deployed to maintain this high quality in the preparedness for laboratory accreditation and support to clinical trials.
Collapse
Affiliation(s)
- N Coulibaly
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Kone
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Diarra
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A B Cisse
- National Referral Laboratory of Mycobacteriology, National Institute of Public Health, INSP, Bamako, Mali
| | - O Kodio
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - G Coulibaly
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Kone
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Baya
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Maiga
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali; Center for Global Health, Northwestern University, Chicago, IL, USA
| | - D Dabitao
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Belson
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - S Dao
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Diallo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Diakite
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A H Babana
- Microbiology and Biotechnology Research Laboratory, Faculty of Sciences and Techniques, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| |
Collapse
|
5
|
Diarra B, Tolofoudie M, Sarro YS, Togo ACG, Bane S, Nientao I, Cisse AB, Kone M, Somboro A, Degoga B, Diallo F, Coulibaly G, Kodio O, Sanogo M, Kone B, Diabate S, Baya B, Kone A, Dabitao D, Maiga M, Belson M, Dao S, Maiga II, Murphy RL, Siddiqui S, Toloba Y, Konate B, Doumbia S, de Jong BC, Diallo S. Diabetes Mellitus among new tuberculosis patients in Bamako, Mali. J Clin Tuberc Other Mycobact Dis 2019; 17:100128. [PMID: 31788570 PMCID: PMC6879999 DOI: 10.1016/j.jctube.2019.100128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Introduction Diabetes Mellitus (DM) increases worldwide, mostly in low- and middle-income countries. In Mali, the prevalence in the adult population is estimated at 1.8%, but tuberculosis (TB) patients are not systematically screened. The goal of our study was to determine the prevalence of DM among newly diagnosed TB patients. Methods We conducted a cross sectional study and a pilot prospective cohort study in four health centers in Bamako. All patients underwent fasting capillary-blood glucose (FCBG) test at Day 0, and repeated after one-week of TB treatment. Venous FBG test was performed for discrepancies between the two FCBG results. Thereafter, FCBG was performed for pilot study at month-2 (M2) and M5 of TB treatment. Results Two hundred and one patients were enrolled in this study. Impaired fasting blood glucose was identified in 17 (8.5%), of whom 11 (5.5%) had DM (VFBG >7 mmol/L). Among patients with DM, seven (63.6%) had successful TB treatment outcome, versus 142 (74.7%) of those without DM (p = 0.64), and (OR: 1.69, 95%CI 0.47–6.02). Conclusion The prevalence of DM among TB patients in Bamako exceeds that of the general population and screening at TB diagnosis suffices to identify those with DM. Systematic screening of both diseases will allow better treatment.
Collapse
Affiliation(s)
- B Diarra
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - M Tolofoudie
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Bane
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - I Nientao
- Service de Médecine et d'Endocrinologie de l'hôpital du Mali, Bamako, Mali
| | - A B Cisse
- Laboratoire National de Référence des Mycobactéries (LNR), Institut National de Recherche en Santé publique (INRSP), Bamako, Mali
| | - M Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Somboro
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Degoga
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - F Diallo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - G Coulibaly
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O Kodio
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Sanogo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Diabate
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Baya
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - D Dabitao
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Maiga
- Global Health, Northwestern University, Chicago, IL, United States
| | - M Belson
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
| | - S Dao
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - I I Maiga
- Laboratoire d'analyses Médicales et Hygiène Hospitalière du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - R L Murphy
- Global Health, Northwestern University, Chicago, IL, United States
| | - S Siddiqui
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
| | - Y Toloba
- Service de Pneumo-phtisiologie du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - B Konate
- Programme National de Lutte contre la Tuberculose (PNLT), Ministère de la santé et de l'hygiène publique, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B C de Jong
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - S Diallo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
6
|
Baya B, Achenbach CJ, Kone B, Toloba Y, Dabitao DK, Diarra B, Goita D, Diabaté S, Maiga M, Soumare D, Ouattara K, Kanoute T, Berthe G, Kamia YM, Sarro YDS, Sanogo M, Togo ACG, Dembele BPP, Coulibaly N, Kone A, Akanbi M, Belson M, Dao S, Orsega S, Siddiqui S, Doumbia S, Murphy RL, Diallo S. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis 2019; 81:149-155. [PMID: 30772470 PMCID: PMC6481646 DOI: 10.1016/j.ijid.2019.02.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 02/04/2019] [Accepted: 02/08/2019] [Indexed: 11/26/2022] Open
Abstract
Background MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. Methods We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. Results We found that age ≤40years (OR = 2.56. 95% CI: 1.44–4.55), two courses of prior TB treatment (OR = 3.25,95% CI: 1.44–7.30), TB treatment failure (OR = 3.82,95% CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR = 1.98, 95% CI: 1.13–3.48) and a history of contact with a TB patient (OR = 2.48, 95% CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR = 0.88, 95% CI: 0.34–1.94). Conclusion We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.
Collapse
Affiliation(s)
- Bocar Baya
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | | | - Bourahima Kone
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Yacouba Toloba
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Djeneba K Dabitao
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Bassirou Diarra
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Drissa Goita
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Seydou Diabaté
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Mamoudou Maiga
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Northwestern University, Chicago, IL, USA.
| | - Dianguina Soumare
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Khadidia Ouattara
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Tenin Kanoute
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Gaoussou Berthe
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Youssouf M Kamia
- Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali.
| | - Yeya Dit Sadio Sarro
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Moumine Sanogo
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Antieme C G Togo
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Bindongo P P Dembele
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Nadie Coulibaly
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Amadou Kone
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | | | - Michael Belson
- National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA.
| | - Sounkalo Dao
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | - Susan Orsega
- National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA.
| | - Sophia Siddiqui
- National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA.
| | - Seydou Doumbia
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| | | | - Souleymane Diallo
- University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
| |
Collapse
|
7
|
Kone A, Diarra B, Cohen K, Diabate S, Kone B, Diakite MT, Diarra H, Sanogo M, Togo ACG, Sarro YDS, Baya B, Coulibaly N, Kodio O, Achenbach CJ, Murphy RL, Holl JL, Siddiqui S, Doumbia S, Bishai WR, Diallo S, Maiga M. Differential HLA allele frequency in Mycobacterium africanum vs Mycobacterium tuberculosis in Mali. HLA 2019; 93:24-31. [PMID: 30516034 DOI: 10.1111/tan.13448] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2018] [Revised: 10/22/2018] [Accepted: 11/28/2018] [Indexed: 11/28/2022]
Abstract
Tuberculosis (TB) is caused by Mycobacterium tuberculosis complex (MTBC), however, the distribution and frequency of MTBC lineages and sublineages vary in different parts of the globe. Mycobacterium africanum, a member of MTBC is responsible for a large percentage of TB cases in West Africa, however, it is rarely identified outside of this part of the World. Whether or not differential HLA polymorphism (an important host factor) is contributing to the geographic restriction of M. africanum to West Africa is unknown. Here, we conducted a cohort study in Mali of newly diagnosed individuals with active pulmonary TB and normal healthy controls. The MTBC isolates were spoligotyped to determine the TB study groups (M. tuberculosis sensu stricto LAM10 and M. africanum), and HLA typing was performed on peripheral blood. Unlike previous reports on other populations, we found that HLA class-I alleles were significantly associated with active TB disease in this population. HLA-B alleles (B*07:02, B*08:01, B*14:02, B*15:03, B*15:10, B*18:01, B*42:01, B*42:02, B*51:01 and B*81:01) were significantly associated with M. africanum (40%-45%) and M. tuberculosis (75%) compared with healthy controls. Many HLA-A alleles (A*02:05, A*34:02, A*66:01 and A*68:02) were also associated with both TB groups (65%-70%). However, many class II HLA-DR variants were found to be associated with M. tuberculosis but not M. africanum with the exception of the DRB1*03:01, which was associated with both groups. The differential HLA distribution observed in this study might be at least partially responsible for the geographical restriction of M. africanum infections to West Africa.
Collapse
Affiliation(s)
- Amadou Kone
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Bassirou Diarra
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Keira Cohen
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Seydou Diabate
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Bourahima Kone
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Mahamane T Diakite
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Hawa Diarra
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Moumine Sanogo
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Antieme C G Togo
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Yeya Dit Sadio Sarro
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Bocar Baya
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Nadie Coulibaly
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Ousmane Kodio
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | | | | | | | - Sophia Siddiqui
- National Institute of Allergic and Infectious Diseases, Rockville, Maryland
| | - Seydou Doumbia
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - William R Bishai
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Souleymane Diallo
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Mamoudou Maiga
- University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.,Northwestern University, Chicago, Illinois
| |
Collapse
|
8
|
Diarra B, Safronetz D, Sarro YDS, Kone A, Sanogo M, Tounkara S, Togo ACG, Daou F, Maiga AI, Dao S, Rosenke K, Falzarano D, Doumbia S, Zoon KC, Polis M, Siddiqui S, Sow S, Schwan TG, Feldmann H, Diallo S, Koita OA. Laboratory Response to 2014 Ebola Virus Outbreak in Mali. J Infect Dis 2017; 214:S164-S168. [PMID: 27707892 DOI: 10.1093/infdis/jiw200] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Aware of the rapid spread of Ebola virus (EBOV) during the current West African epidemic, Mali took several proactive steps to rapidly identify cases within its borders. Under the Mali International Center for Excellence in Research program, a collaboration between the National Institute of Allergy and Infectious Diseases and the Malian Ministry of Higher Education and Scientific Research established a national EBOV diagnostic site at the University of Sciences, Techniques and Technologies of Bamako in the SEREFO Laboratory. Two separate introductions of EBOV occurred in Mali from neighboring Guinea, but both chains of transmission were quickly halted, and Mali was declared "Ebola free" on 18 January 2015 and has remained so since. The SEREFO Laboratory was instrumental in the success of Mali's Ebola response by providing timely and accurate diagnostics. As of today, the SEREFO Laboratory has tested 103 samples from 88 suspected cases, 10 of which were EBOV positive, since the Ebola diagnostics unit started in April 2014. The establishment of Ebola diagnostics in the SEREFO Laboratory, safety precautions, and diagnostics are described.
Collapse
Affiliation(s)
- Bassirou Diarra
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | | | - Yeya Dit Sadio Sarro
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Amadou Kone
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Moumine Sanogo
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Sady Tounkara
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Antieme C G Togo
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Fatoumata Daou
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Almoustapha I Maiga
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Sounkalo Dao
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | | | | | - Seydou Doumbia
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Kathryn C Zoon
- Cytokine Biology Section, Division of Intramural Research
| | - Michael Polis
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Sophia Siddiqui
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Samba Sow
- Centre des Operations d'Urgence (Malian Center for Emergency Operations), Centre National d'Appui a la lutte contre la Maladie (Malian Center for Disease Control), Ministry of Health, Bamako, Mali
| | - Tom G Schwan
- Laboratory of Zoonotic Pathogens, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
| | | | - Souleyman Diallo
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| | - Ousmane A Koita
- SEREFO Laboratory, University Clinical Research Center, Faculty of Sciences and Technology, University of Sciences, Techniques and Technologies of Bamako, Mali
| |
Collapse
|
9
|
Kone B, Maiga M, Baya B, Sarro YDS, Coulibaly N, Kone A, Diarra B, Sanogo M, Togo ACG, Goita D, Dembele M, Polis MA, Warfield J, Belson M, Dao S, Orsega S, Murphy RL, Diallo S, Siddiqui S. Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults. J Blood Lymph 2017; 7:154. [PMID: 29423342 PMCID: PMC5800422 DOI: 10.4172/2165-7831.1000154] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION Measurement of immuno-hematological parameters has been historically helpful in the diagnosis and treatment monitoring of many infectious diseases and cancers. However, these parameters have not yet been established in many developing countries where patient care strongly relies on such low-cost tests. This study describes the immuno-hematological parameter ranges for Malian healthy adults. METHODS A cross sectional study was conducted from August 2004 to May 2013. We included 213 healthy volunteers (173 male and 40 female), aged between 18-59 years. Median, 2.5 and 97.5 percentile ranges for each immuno-hematological parameter are presented. RESULTS In our study population, the hematological parameters' ranges were mostly different to the universal established ranges. We found in our population a Median white blood cell (WBC) count of 5200 cells/μL [3237.5-11900], Red Blood Cell (RBC) count of 4.94 10^6 [3.56-6.17], hemoglobin (Hb) of 14.2 g/dL [12.2-17.38], platelet count (Plt) of 275 10^3/μL [145.4-614.4], lymphocytes 2050/μL [1200-3800], neutrophils 2200/μL [1040-6220]; monocytes 200/μL [100-660]; eosinophils 131/μL [0-1026]; CD4 902 cells/μL [444-1669] and CD8 485 cells/μL [0-1272]. We found significant gender differences in RBC, Hb level and MPV. However, RBC and Hb were higher in males median values compared to females (median values) (p<0.001), whereas the Mean platelet volume lower values (MPV) in males than females (P<0.047). The hemoglobin level for some West African countries (Mali, Burkina Faso, Togo, and Nigeria) ranged from 13.5 to 15.1 g/dL for males and 12 to 13 g/dL for females. However in East and Southern Africa, the values were anywhere from 14.1 to 16.1 for males and 11.2 to 14.4 for females. CONCLUSION Our data may help physicians to better define hematological abnormalities in patients. They may also be used to define new "normal hematological values" in Malian population or in the whole West African population.
Collapse
Affiliation(s)
- B Kone
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Maiga
- University of Sciences, Techniques and Technologies of Bamako, Mali
- Leidos Biomedical Research, Inc., in support to NIAID, Bethesda, Maryland, USA
- Northwestern University, Chicago, Illinois, USA
| | - B Baya
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - YDS Sarro
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - N Coulibaly
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - A Kone
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - B Diarra
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Sanogo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - ACG Togo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - D Goita
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Dembele
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - MA Polis
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - J Warfield
- Leidos Biomedical Research, Inc., in support to NIAID, Bethesda, Maryland, USA
| | - M Belson
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - S Dao
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - S Orsega
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - RL Murphy
- Northwestern University, Chicago, Illinois, USA
| | - S Diallo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - S Siddiqui
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| |
Collapse
|
10
|
Sanogo M, Kone B, Diarra B, Maiga M, Baya B, Somboro AM, Sarro YS, Togo ACG, Dembele BPP, Goita D, Kone A, M'Baye O, Coulibaly N, Diabate S, Traore B, Diallo MH, Coulibaly YI, Saleeb P, Belson M, Orsega S, Siddiqui S, Polis MA, Dao S, Murphy RL, Diallo S. Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali. Clin Microbiol Infect 2017; 23:408.e1-408.e6. [PMID: 28110049 DOI: 10.1016/j.cmi.2017.01.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 11/08/2016] [Accepted: 01/04/2017] [Indexed: 01/01/2023]
Abstract
OBJECTIVES In Mali early detection and treatment of multidrug-resistant tuberculosis (MDR-TB) are still challenging due to the cost, time and/or complexity associated with regular tests. Microscopic Observation Drug Susceptibility (MODS) is a low-cost assay validated by WHO in 2010. It is a liquid-culture-based assay to detect the 'cording' characteristic of Mycobacterium tuberculosis complex and to assess susceptibility to both isoniazid and rifampicin defining multidrug-resistant tuberculosis (MDR-TB). In this study we aimed to evaluate the performance of MODS as diagnostic tool compared with a validated method-Mycobacteria Growth Indicator Tube/Antimicrobial Susceptibility Testing/Streptomycin, Isoniazid, Rifampicin and Ethambutol (MGIT/AST/SIRE). METHODS AND RESULTS Between January 2010 and October 2015 we included 98 patients with suspected TB in an observational cohort study. The sensitivity and specificity of MODS assay for detecting TB were respectively 94.12% and 85.71% compared with the reference MGIT/7H11 culture, with a Cohen κ coefficient of 0.78 (95% CI 0.517-1.043). The median time to culture positivity for MODS assay and MGIT (plus interquartile range, IQR) was respectively 8 days (IQR 5-11) and 6 days (IQR 5-6). In detecting patients with MDR-TB, the sensitivity and specificity of MODS assay were respectively 100% and 95.92%. The positive predictive value and negative predictive value were, respectively, 66.7% and 100%. The median turnaround times for obtaining MDR-TB results using MODS assay and MGIT/AST/SIRE was respectively 9 days and 35 days. Hence, the MODS assay rapidly identifies MDR-TB in Mali compared with the MGIT/AST/SIRE. CONCLUSION As an easy, simple, fast and affordable method, the MODS assay could significantly improve the management of TB.
Collapse
Affiliation(s)
- M Sanogo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Diarra
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Institute of Tropical Medicine (ITM), Biomedical Department, Antwerp, Belgium.
| | - M Maiga
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA
| | - B Baya
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A M Somboro
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B P P Dembele
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - D Goita
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O M'Baye
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - N Coulibaly
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Diabate
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Traore
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M H Diallo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y I Coulibaly
- Filariasis Unit of the Malaria Research and Training Centre (MRTC), USTTB, Bamako, Mali
| | - P Saleeb
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - M Belson
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Orsega
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Siddiqui
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - M A Polis
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Dao
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - R L Murphy
- Division of Infectious Diseases, Northwestern University, Chicago, IL, USA
| | - S Diallo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
11
|
Diarra B, Goita D, Tounkara S, Sanogo M, Baya B, Togo ACG, Maiga M, Sarro YS, Kone A, Kone B, M'Baye O, Coulibaly N, Kassambara H, Cisse A, Belson M, Polis MA, Otu J, Gehre F, Antonio M, Dao S, Siddiqui S, Murphy RL, de Jong BC, Diallo S. Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014. BMC Infect Dis 2016; 16:714. [PMID: 27894266 PMCID: PMC5126865 DOI: 10.1186/s12879-016-2060-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Accepted: 11/22/2016] [Indexed: 12/02/2022] Open
Abstract
Background Although Drug resistance tuberculosis is not a new phenomenon, Mali remains one of the “blank” countries without systematic data. Methods Between 2006 and 2014, we enrolled pulmonary TB patients from local TB diagnostics centers and a university referral hospital in several observational cohort studies. These consecutive patients had first line drug susceptibility testing (DST) performed on their isolates. A subset of MDR was subsequently tested for second line drug resistance. Results A total of 1186 mycobacterial cultures were performed on samples from 522 patients, including 1105 sputa and 81 blood samples, yielding one or more Mycobacterium tuberculosis complex (Mtbc) positive cultures for 343 patients. Phenotypic DST was performed on 337 (98.3%) unique Mtbc isolates, of which 127 (37.7%) were resistant to at least one drug, including 75 (22.3%) with multidrug resistance (MDR). The overall prevalence of MDR-TB was 3.4% among new patients and 66.3% among retreatment patients. Second line DST was available for 38 (50.7%) of MDR patients and seven (18.4%) had resistance to either fluoroquinolones or second-line injectable drugs. Conclusion The drug resistance levels, including MDR, found in this study are relatively high, likely related to the selected referral population. While worrisome, the numbers remained stable over the study period. These findings prompt a nationwide drug resistance survey, as well as continuous surveillance of all retreatment patients, which will provide more accurate results on countrywide drug resistance rates and ensure that MDR patients access appropriate second line treatment. Electronic supplementary material The online version of this article (doi:10.1186/s12879-016-2060-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- B Diarra
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. .,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
| | - D Goita
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Tounkara
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Sanogo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Baya
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Maiga
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O M'Baye
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - N Coulibaly
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - H Kassambara
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Cisse
- Laboratoire National de Référence des Mycobactéries (LNR), Institut National de Recherche en Santé publique (INRSP), Bamako, Mali
| | - M Belson
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - M A Polis
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - J Otu
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia
| | - F Gehre
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia.,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - M Antonio
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia.,Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.,Microbiology and Infection Unit, Warwick Medical School, University of Warwick, Coventry, UK
| | - S Dao
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Siddiqui
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - R L Murphy
- Global Health, Northwestern University, Chicago, IL, USA
| | - B C de Jong
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - S Diallo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
12
|
Diarra B, Cissé AB, Kodio O, Sanogo M, Baya B, Togo ACG, Somboro A, Tolofoudié M, Degoga B, Keita ML, Diallo F, Nguiakam N, Coulibaly G, Bane S, Sarro YDS, Doumbia S, Murphy RL, Diallo S, Dejong BC. Screening new tuberculosis patients in Mali for rifampicin resistance at 2months. Int J Mycobacteriol 2016; 5 Suppl 1:S42-S43. [PMID: 28043602 DOI: 10.1016/j.ijmyco.2016.09.052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2016] [Accepted: 09/20/2016] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE/BACKGROUND The recent call for universal drug susceptibility testing (DST) for all tuberculosis (TB) patients will be difficult to meet in settings where Xpert rollout is limited, such as low prevalence of HIV and Multi-drug Resistant Tuberculosis (MDR) settings. As recommended by World Health Organization (WHO) guidelines, the success of TB treatment is measured by Ziehl-Neelsen (ZN) microscopy or auramine-rhodamine fluorescent microscopy (FM) on sputum, in which conversion to negative smear at 2months (M) is an important predictor of treatment success, defined as a negative smear at 5M. The sputum smear that fails to convert to negative at 5M are screened for rifampicin resistance. We tested in a prospective study whether an early screen for rifampicin resistance, based on FM results at 2M, could detect MDR patients early, rather than screening all patients with GeneXpert MTB/Rif at baseline. METHODS Between February 2015 and August 2016, we enrolled new TB patients in an IRB-approved prospective cohort study at four health centers in Bamako district. Fresh sputum samples were collected at 2M and 5M to measure FM smear conversion. Patients who failed to show a decline in FM positivity at 2M (moderate or many Acid Fast Bacilli (AFB)) had their sputum tested in GeneXpert to detect rifampicin resistance. Patients who had any AFB seen at 5M were also tested using GeneXpert. RESULTS Of the 570 patients who were enrolled in the study, 22 (3.8%) died and 27 (4.7%) were lost to follow-up. The prevalence of HIV and TB coinfection was 12.4%, and 65.6% of the patients were male. At 2M, 32 out of 429 patients still had moderate or many AFBs in FM, and were screened by Xpert, of whom 5 (15.6%) tested rifampicin-resistant and were referred for MDR treatment. Of the 310 patients who completed 5M of treatment, 35 (11.3%) met the definition of failure (few or moderate AFB in FM) and had their sputum tested in Xpert; moreover, four (11.4%) demonstrated rifampicin resistance. In total, 67 (21.6% of 310) patients were screened by Xpert, of whom nine were detected to have MDR (or 13.4% of those screened). CONCLUSION Although we cannot exclude additional MDR patients having been missed by our screening strategy, our screening algorithm at 2M detected five out of nine MDR patients. Detecting patients at 2M allowed for earlier referral, and potentially less acquired drug resistance and lower mortality. This strategy may be advantageous while awaiting further rollout of Xpert machines that will permit universal DST.
Collapse
Affiliation(s)
- Bassirou Diarra
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali.
| | - Aissata B Cissé
- Tuberculosis National Reference Laboratory, Institut National de Référence en Santé Publique, Bamako, Mali
| | - Ousmane Kodio
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Moumine Sanogo
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Bocar Baya
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Antieme C G Togo
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Amadou Somboro
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Mohamed Tolofoudié
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Boureima Degoga
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Marie Laure Keita
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Fatimata Diallo
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Natacha Nguiakam
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Gagni Coulibaly
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Sidy Bane
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Yeya Dit Sadio Sarro
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Seydou Doumbia
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | | | - Souleymane Diallo
- SEREFO/UCRC, University Clinical Research Center, Techniques and Technologies of Bamako, Bamako, Mali
| | - Bouke C Dejong
- Mycobacteriology Unit, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
| |
Collapse
|
13
|
Diallo M, Diarra B, Sanogo M, Togo ACG, Somboro AM, Diallo MH, Traoré B, Maiga M, Koné Y, Tounkara K, Sarro YDS, Baya B, Goita D, Kassambara H, Dembélé BPP, Siddiqui S, Murphy RL, Dao S, Diallo S, Tounkara A, Niang M. Molecular identification of Mycobacterium bovis from cattle and human host in Mali: expanded genetic diversity. BMC Vet Res 2016; 12:145. [PMID: 27439708 PMCID: PMC4955238 DOI: 10.1186/s12917-016-0768-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 07/12/2016] [Indexed: 11/10/2022] Open
Abstract
Background Bovine tuberculosis (BTB) is a contagious, debilitating human and animal disease caused by Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex. The study objective were to estimate the frequency of BTB, examine genetic diversity of the M. bovis population in cattle from five regions in Mali and to determine whether M. bovis is involved in active tuberculosis (TB) in humans. Samples from suspected lesions on cattle at the slaughterhouses were collected. Mycobacterial smear, culture confirmation, and spoligotyping were used for diagnosis and species identification. Mycobacterium DNA from TB patients was spoligotyped to identify M. bovis. Results In total, 675 cattle have been examined for lesions in the five regions of Mali. Out of 675 cattle, 79 specimens presented lesions and then examined for the presence of M. bovis. Thus, 19 (24.1 %) were identified as M. bovis; eight (10.1 %) were non-tuberculous Mycobacterium (NTM). Nineteen spoligotype patterns were identified among 79 samples with five novel patterns. One case of M. bovis (spoligotype pattern SB0300) was identified among 67 TB patients. Conclusion This study estimates a relatively true proportion of BTB in the regions of Mali and reveals new spoligotype patterns.
Collapse
Affiliation(s)
| | - Bassirou Diarra
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali.
| | - Moumine Sanogo
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Antieme C G Togo
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Anou M Somboro
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Mariam H Diallo
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Bréhima Traoré
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Mamoudou Maiga
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | | | | | - Yeya Dit Sadio Sarro
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Bocar Baya
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Drissa Goita
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Hamadoun Kassambara
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Bindongo P P Dembélé
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | | | | | - Sounkalo Dao
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Souleymane Diallo
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | - Anatole Tounkara
- SEREFO, University of Sciences, Techniques and Technologies of Bamako (USTTB), Point-G, Bamako, Mali
| | | |
Collapse
|
14
|
Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA, Diarra B, Fall IS, Haidara FC, Diallo F, Sanogo M, Sarro YS, Kone A, Togo ACG, Traore A, Kodio M, Dosseh A, Rosenke K, de Wit E, Feldmann F, Ebihara H, Munster VJ, Zoon KC, Feldmann H, Sow S. Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 2015; 348:117-9. [PMID: 25814067 PMCID: PMC11045032 DOI: 10.1126/science.aaa5646] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Accepted: 02/23/2015] [Indexed: 01/26/2023]
Abstract
The occurrence of Ebola virus (EBOV) in West Africa during 2013-2015 is unprecedented. Early reports suggested that in this outbreak EBOV is mutating twice as fast as previously observed, which indicates the potential for changes in transmissibility and virulence and could render current molecular diagnostics and countermeasures ineffective. We have determined additional full-length sequences from two clusters of imported EBOV infections into Mali, and we show that the nucleotide substitution rate (9.6 × 10(-4) substitutions per site per year) is consistent with rates observed in Central African outbreaks. In addition, overall variation among all genotypes observed remains low. Thus, our data indicate that EBOV is not undergoing rapid evolution in humans during the current outbreak. This finding has important implications for outbreak response and public health decisions and should alleviate several previously raised concerns.
Collapse
Affiliation(s)
- T Hoenen
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - D Safronetz
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - A Groseth
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - K R Wollenberg
- Bioinformatics and Computational Biosciences Branch, NIAID, NIH, Bethesda, MD 20892, USA
| | - O A Koita
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - B Diarra
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - I S Fall
- World Health Organization Office, Bamako, Mali
| | - F C Haidara
- Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali
| | - F Diallo
- Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali
| | - M Sanogo
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - Y S Sarro
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - A Kone
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - A C G Togo
- Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali
| | - A Traore
- Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali
| | - M Kodio
- Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali
| | - A Dosseh
- World Health Organization Inter-Country Support Team, Ouagadougou, Burkina Faso
| | - K Rosenke
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - E de Wit
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - F Feldmann
- Rocky Mountain Veterinary Branch, Division of Intramural Research, NIAID, NIH, Hamilton, MT 59840, USA
| | - H Ebihara
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - V J Munster
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA
| | - K C Zoon
- Office of the Scientific Director, NIAID, NIH, Bethesda, MD 20895, USA
| | - H Feldmann
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA.
| | - S Sow
- Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali.
| |
Collapse
|